REXAHN Trademark

Trademark Overview

On Friday, December 20, 2002, a trademark application was filed for REXAHN with the United States Patent and Trademark Office. The USPTO has given the REXAHN trademark a serial number of 76477157. The federal status of this trademark filing is REGISTERED AND RENEWED as of Friday, February 21, 2014. This trademark is owned by Rexahn Corporation. The REXAHN trademark is filed in the Pharmaceutical Products category with the following description:

Therapeutic pharmaceuticals for the treatment of cancer, neuro-degenerative disease, infectious disease, and immune-related disease
rexahn

General Information

Serial Number76477157
Word MarkREXAHN
Filing DateFriday, December 20, 2002
Status800 - REGISTERED AND RENEWED
Status DateFriday, February 21, 2014
Registration Number2839679
Registration DateTuesday, May 11, 2004
Mark Drawing1 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, February 17, 2004

Trademark Statements

Goods and ServicesTherapeutic pharmaceuticals for the treatment of cancer, neuro-degenerative disease, infectious disease, and immune-related disease

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, January 6, 2003
Primary Code005
First Use Anywhere DateMonday, March 19, 2001
First Use In Commerce DateWednesday, November 27, 2002

Trademark Owner History

Party NameREXAHN PHARMACEUTICALS, INC.
Party Type31 - New Owner After Registration
Legal Entity Type03 - Corporation
AddressROCKVILLE, MD 20850
Party NameRexahn Corporation
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressRockville, MD 20850
Party NameRexahn Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressRockville, MD 20850
Party NameRexahn Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressRockville, MD 20850

Trademark Events

Event DateEvent Description
Thursday, March 20, 2003ASSIGNED TO EXAMINER
Thursday, April 17, 2003NON-FINAL ACTION MAILED
Tuesday, October 7, 2003PAPER RECEIVED
Thursday, November 20, 2003PAPER RECEIVED
Wednesday, February 3, 2010AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Tuesday, October 7, 2003CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, November 11, 2003APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, December 9, 2003PREVIOUS ALLOWANCE COUNT WITHDRAWN
Wednesday, December 10, 2003EXAMINERS AMENDMENT MAILED
Monday, December 15, 2003APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 28, 2004NOTICE OF PUBLICATION
Tuesday, February 17, 2004PUBLISHED FOR OPPOSITION
Tuesday, May 11, 2004REGISTERED-PRINCIPAL REGISTER
Friday, February 21, 2014REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Friday, February 21, 2014REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Friday, February 21, 2014NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Thursday, March 18, 2010TEAS SECTION 8 & 15 RECEIVED
Wednesday, March 31, 2010CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, March 31, 2010REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Wednesday, February 5, 2014TEAS SECTION 8 & 9 RECEIVED
Wednesday, February 19, 2014CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, February 19, 2014POST REGISTRATION ACTION MAILED - SEC. 8 & 9
Wednesday, February 19, 2014TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Wednesday, August 15, 2018TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, August 12, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, August 12, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, August 12, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, May 11, 2023COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED

Related Keywords

rexahn disease infectious immune related degenerative neuro pharmaceuticals treatment cancer therapeutic